Last reviewed · How we verify
ramosetron, ondansetron, dexamethasone
This is a combination of three antiemetic agents: ramosetron and ondansetron block 5-HT3 receptors to prevent nausea/vomiting, while dexamethasone is a corticosteroid that reduces inflammation and enhances antiemetic effects.
This is a combination of three antiemetic agents: ramosetron and ondansetron block 5-HT3 receptors to prevent nausea/vomiting, while dexamethasone is a corticosteroid that reduces inflammation and enhances antiemetic effects. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).
At a glance
| Generic name | ramosetron, ondansetron, dexamethasone |
|---|---|
| Also known as | anti-emetics |
| Sponsor | Government Medical College, Haldwani |
| Drug class | 5-HT3 receptor antagonist + corticosteroid combination |
| Target | 5-HT3 receptor (ramosetron, ondansetron); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Supportive Care |
| Phase | FDA-approved |
Mechanism of action
Ramosetron and ondansetron are selective 5-hydroxytryptamine-3 (5-HT3) receptor antagonists that block serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract, preventing chemotherapy-induced and postoperative nausea and vomiting. Dexamethasone, a glucocorticoid, potentiates this effect through anti-inflammatory mechanisms and modulation of neurotransmitter pathways involved in emesis. The combination provides synergistic antiemetic coverage across multiple pathways.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
Common side effects
- Headache
- Constipation
- Diarrhea
- Dizziness
- Hyperglycemia (dexamethasone-related)
- Insomnia
Key clinical trials
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (NA)
- The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints (NA)
- Post-operative Nausea Vomiting in Laparoscopic Cholecystectomy (PHASE4)
- Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: